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ABSTRACT
Au(NHC) and Au(NHC)2, i.e. a monocarbene gold(I) complex and the 
corresponding bis(carbene) complex, are two structurally related compounds, 
endowed with cytotoxic properties against several cancer cell lines. Herein, we 
explore the molecular and cellular mechanisms at the basis of their cytotoxicity 
in A2780 human ovarian cancer cells. Through a comparative proteomic analysis, 
we demonstrated that the number of modulated proteins is far larger in Au(NHC)2-
treated than in Au(NHC)-treated A2780 cells. Both gold compounds mainly affected 
proteins belonging to the following functional classes: protein synthesis, metabolism, 
cytoskeleton and stress response and chaperones. Particularly, Au(NHC)2 gave rise 
to an evident upregulation of several glycolytic enzymes. Moreover, only Au(NHC)2 
triggered a net impairment of respiration and a metabolic shift towards glycolysis, 
suggesting that mitochondria are relevant cellular targets. We also found that both 
carbenes, similarly to the gold(I) compound auranofin, caused a strong inhibition of 
the seleno-enzyme thioredoxin reductase (TrxR). In conclusion, we highlighted that 
coordination of two carbene ligands to the same gold(I) center greatly enhances the 
antiproliferative effects of the resulting compound in comparison to the monocarbene 
derivative. Moreover, TrxR inhibition and metabolic impairment seem to play a major 
role in the Au(NHC)2 cytotoxicity. Overall, these antiproliferative effects were also 
confirmed on other two human ovarian cancer cell lines (i.e. SKOV3 and IGROV1).
INTRODUCTION
Ovarian cancer is the 7th most common cancer in 
women worldwide with an estimated incidence rate of 6.1 
per 100,000 [1]. In addition, it represents the 8th cause of 
death from cancer in women worldwide [1]. Such dismal 
prognosis is due to several factors, including that most of 
ovarian cancer cases are diagnosed with advanced disease 
[2]. Ovarian cancer chemotherapy is mainly represented 
by combinations of carboplatin and paclitaxel both in 
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the adjuvant and metastatic settings. Although ovarian 
cancer is considered a chemosensitive cancer, tumor drug 
resistance develops in most of cases. To date, in addition 
to other cytotoxic drugs, several targeted agents such 
as PARP inhibitors (e.g. olaparib, rucaparib) or the anti 
VEGF MoAb bevacizumab may be used in ovarian cancer 
patients whose disease recurred [3]. However, despite 
the availability of such new treatment options, five-year 
overall survival of all stage ovarian cancer is below 50% 
[1, 4].
Thus, there is a strong need for novel, highly 
effective therapies for the treatment of advanced epithelial 
ovarian cancer. The discovery of cisplatin’s antitumor 
activity in 1969 prompted the search for novel metal-
containing complexes as potential anticancer drugs. 
Among the several non-platinum drugs considered so far, 
gold-based compounds are gaining ever-growing attention. 
Gold has been largely used in medicine since very 
ancient times. Currently, the gold(I) complex auranofin, 
(1-thio-β-D-glucopyranose-2,3,4,6-tetraacetato-S) 
(triethylphosphine) gold(I)), is clinically used in severe 
forms of rheumatoid arthritis, and its anticancer potential 
was already described in both in vitro and in vivo models 
[5, 6]. Moreover, clinical trials including auranofin are 
currently ongoing also in ovarian cancer patients [7, 8].
Overall, gold compounds constitute a variegate 
family of very promising experimental agents for 
cancer treatment. Indeed, several gold(I) and gold(III) 
complexes were recently shown to manifest outstanding 
antiproliferative properties in vitro against selected 
human cancer cell lines, and some of them performed 
remarkably well even in in vivo cancer models [9, 10]. As 
previously mentioned, investigations on the cytotoxicity 
scores of gold complexes were initially focused on 
auranofin and its analogues, which present linear gold 
phosphane structures [11, 12]. More recently, a variety 
of gold derivatives has been tested as potential antitumor 
agents, including organogold derivatives, complexes with 
polydentate nitrogen donor ligands, gold porphyrins, gold 
dithiocarbamates, and gold-N-heterocyclic carbene (NHC) 
[13–17]. Based on the great structural variety of the used 
ligands and their role in controlling the reactivity of the 
gold centre, a unique mode of action or pharmacological 
profile is unlikely to exist. Gold compounds can trigger 
cell death through a multitude of mechanisms by affecting 
mitochondria and the redox balance, by modulating cell 
cycle, by controlling proteolysis and signal transduction 
[18–23]. Though the detailed mechanisms of action remain 
unclear, the inhibition of the seleno-enzyme thioredoxin 
reductase (TrxR) seems to be a common mechanistic 
trait to explain, at least partially, the cytotoxic actions of 
several gold(I) and gold(III) complexes, as strong TrxR 
inhibition may eventually lead to cancer cell apoptosis 
through activation of a mitochondrial pathway [24–28].
N-Heterocyclic carbenes (NHCs) are very 
interesting gold(I) ligands as they manifest donor 
properties similar to phosphines, thus affording a very 
stable gold(I) coordination. Hydrophilic/lipophilic 
properties can be readily fine-tuned by the incorporation 
of appropriate functional groups on the carbene moieties. 
Within this frame, several gold carbene complexes were 
prepared and characterized during the past few years that 
turned out particularly effective and promising from the 
biological and pharmacological point of view [29–34]. 
Even though several studies have been carried out so far 
on the cellular effects of gold carbene compounds and 
valuable mechanistic information has been gathered, 
the precise mode of action of gold carbene complexes, 
at the molecular level, is still largely unclear. Based on 
the observations reported so far, gold carbene complexes 
are mainly considered as a class of anti-mitochondrial 
agents [35]. Indeed, recent studies have demonstrated a 
strong selective TrxR inhibition by several gold(I)–NHC 
complexes [26, 35–39]. Similarly, Holenya et al. [40] 
outlined thioredoxin reductase as a central target for a 
new gold(I) carbene complex. Its inhibition may trigger a 
severe metabolic impairment accompanied by activation 
of pro-apoptotic signalling, resulting in cell death.
Within this frame, the present work explored the 
cytotoxic activity of two new gold(I) carbene complexes, 
previously characterized from the chemical point of 
view (Figure 1) [41]. These two structurally related 
compounds are characterised by the presence of one 
(complex 1: Au(NHC)Cl, i.e. Au(NHC)) or two (complex 
2:[Au(NHC)2]PF6, i.e. Au(NHC)2) 1-butyl-3-methyl-
imidazole-2-ylidene moieties acting as NHC ligand 
coordinating the gold(I) centre, with 1 bearing a chloride 
as the second ligand in place of the second NHC. This 
difference renders the two compounds highly distinct even 
in terms of the overall charge as compound 2 is mono-
cationic while compound 1 is neutral. In complex 1 the 
second gold(I) ligand is a chloride ion that, in principle, is 
believed to act as the labile ligand.
Herein, the biological behaviour of these two 
gold carbene complexes has been analysed in A2780 
human ovarian cancer cell line, according to the 
following strategy. First, an extensive proteomic 
investigation study has been carried out according to 
classical procedures aimed at highlighting differences 
in protein expression. Then, these differences were 
analysed through bioinformatics tools leading to 
the identification of specific components of the 
cell machinery that appear to be perturbed by gold 
treatment. Finally, the suggested molecular and cellular 
effects were confirmed through direct measurements of 
cell metabolic activities and cell functioning. Relevant 
differences were highlighted in the cellular effects 
produced by the two-investigated gold(I) carbene 
compounds that might be associated to significant 
mechanistic differences in the mode of action. These 
results were also confirmed on other two human ovarian 
cancer cell lines (i.e. SKOV3 and IGROV1).
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RESULTS
Lipophilicity, cytotoxicity, cell cycle alterations 
and cell death
Lipophilicity expressed by the octanol-water partition 
coefficient as the logarithm of the concentration ratio 
(logP) of a compound in each phase constituting the binary 
immiscible mixture, represents one of the most important 
molecular features for the drug action profile, influencing 
both pharmacokinetic and pharmacodynamics processes. 
LogP value of the two gold(I) carbene complexes, Au(NHC)
Cl and [Au(NHC)2]PF6, has been measured by modification 
of the reported shake-flask method (Table 1) [42]. The 
reported values show that the neutral complex Au(NHC)
Cl (i.e. Au(NHC)) has a far greater lipophilicity than the 
cationic complex [Au(NHC)2]PF6(i.e. Au(NHC)2) in accord 
with expectations, since the positive charge of bis(carbene) 
species greatly increases its affinity for water.
The cytotoxic activity of these gold(I) complexes was 
evaluated in A2780 human ovarian carcinoma cell line by 
cell proliferation assay according to the procedure described 
by Skehan et al. [43] and compared with that of cisplatin. 
The IC50 values, observed after 72 h exposure to each 
carbene complex and cisplatin, are reported in Figure 2A. 
The monocarbene complex Au(NHC) showed an inhibitory 
potential similar to that of cisplatin, giving rise to IC50 
values in the micromolar range (ca. 2 μM). Remarkably, 
the bis(carbene) complex Au(NHC)2 displayed a far 
more pronounced cytotoxicity with IC50 value in the high 
nanomolar range (ca. 0.1 μM). Besides, the antiproliferative 
effect of the carbene complexes in A2780 was evaluated 
by a cell viability assay using 3-(4,5-dimethyl-thiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) that is reduced 
to violet formazan in viable cells. For each complex, a 
time course at 12, 24, 48 and 72 h drug exposure with a 
concentration corresponding to their 72 h-IC50-dose, was 
carried out (Figure 2B). The obtained results were in line 
with those of IC50 experiments. Indeed, the bis(carbene) 
Au(NHC)2 achieved the decrease of 50% cell viability, after 
72 h of incubation, with a dose about 20-fold lower than the 
monocarbene complex Au(NHC).
Afterwards, the effects of carbene complexes on the 
A2780 cell cycle progression were analysed by propidium 
iodide staining and flow cytometry, after 24, 48 and 72 h 
of treatment. In the first 24 h, there were no significant 
differences between carbene-treated and untreated cells 
(data not shown). After 48 h, Au(NHC)2 induced a 
significant accumulation of cells in the G1 phase (about 
80%) followed by a decrease of cell population in S phase 
(about 11%) suggesting an associated cell cycle arrest 
(Figure 2C). Conversely, the behaviour of Au(NHC)-treated 
cells was similar to that of control cells with about 50% of 
cells in G1 phase and 38% in S phase. After 72 h, the cell 
cycle analysis highlighted that Au(NHC)2 and, with smaller 
extent, Au(NHC) were able to induce DNA fragmentation 
corresponding to the appearance of sub-G0/G1 population 
(Supplementary Figure 1). This result suggested that 
A2780 cancer cells could undergo apoptosis under carbene 
treatment as reported for cisplatin and the gold(I) auranofin 
[25]. Therefore, we examined if the selected mono and 
bis(carbene) complexes also favour apoptosis as the 
main way for cell death. We performed flow cytometry 
analysis of annexin V/propidium iodide-stained A2780 
cells treated with Au(NHC) or Au(NHC)2 for 72 h. After 
treatment, the cell-state distribution revealed a pronounced 
antiproliferative effect. As shown in Figure 3A, about 50-
60% of late apoptotic cells were present in both carbene-
treated cells in comparison to control cells. The apoptosis 
induction by Au(NHC) and Au(NHC)2 was supported by 
western blot analysis of the pro-apoptotic Bax and the anti-
apoptotic Bcl2 protein amount. In accord with the flow 
Figure 1: Chemical structure of gold(I)-N-heterocyclic carbene complexes. (A) Au(NHC) and (B) Au(NHC)2.
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cytometry analysis of apoptosis, after 72 h of treatment, 
both Au(NHC) and Au(NHC)2 triggered an increase of Bax 
protein level along with a decrease of Bcl2 protein level 
(Supplementary Figure 2). To elucidate whether apoptosis 
was induced by extrinsic or intrinsic apoptotic signalling 
pathway, we assessed the activation of specific caspases. 
After 72 h of treatment, we analysed by flow cytometry 
the activation of the initiator caspase-8 (extrinsic pathway) 
and caspase-9 (intrinsic pathway) along with the activation 
of the effector caspase-3. As shown in Figure 3B, 3C 
and 3D, both carbene complexes, with a stronger effect 
for bis(carbene), activated the initiator caspase-8. Only 
Au(NHC)2 triggered a significant increased activity of the 
initiator caspase-9 and the effector caspase-3.
Proteomic profile of Au(NHC) and Au(NHC)2 
-treated A2780 cells
To further characterize the cytotoxic and 
antiproliferative mechanism of the mono and bis(carbene) 
complex, proteome profiles of control, Au(NHC) and 
Au(NHC)2 -treated cells were studied by comparative 
2-DE based proteomic analysis. A2780 cells were treated 
for 24 h with mono or bis(carbene) at a concentration 
Figure 2: Antiproliferative activity of Au(NHC) and Au(NHC)2 against A2780 human ovarian cancer cells. (A) Inhibitory 
concentration IC50 (μM) values were obtained after 72 h of treatment according to the procedure described by Skehan et al. [43]. The IC50 
value of cisplatin was also assessed. (B) Cell viability time course upon Au(NHC) and Au(NHC)2 treatment using MTT assay. Values were 
obtained by measuring the percentage of treated-A2780 viable cells relative to untreated controls after 12, 24, 28, 72 h of incubation with 
the 72 h-exposure IC50-dose. (C) Cell cycle distribution was analysed by flow cytometric analysis. Histograms reported the cell percentage 
in G1, S and G2 phase of cell cycle after 48 h of treatment with the 72 h-exposure IC50-dose of Au(NHC) and Au(NHC)2. Flow cytometric 
images are representative of three independent experiments. All the experiments were performed at least in triplicate and results are 
reported as mean ± SD. The statistical analysis was carried out using one-way ANOVA test followed by Tuckey’s multiple comparisons test 
using Graphpad Prism v 6.0 (**p<0.01, ***p<0.001).
Table 1: Measured logP values for carbene 1 and 2
Compound logP
1. Au(NHC)Cl 2.12
2. [Au(NHC)2]PF6 0.06
Oncotarget28046www.oncotarget.com
corresponding to their 72 h-exposure IC50-dose (2 μM and 
0.1 μM, respectively). At this time, cells are viable (as 
shown in MTT time course experiment) and proteomic 
study can allow the early effects of treatments to emerge. 
After carbene treatment, cellular protein extracts were 
prepared and separated by 2-D gel electrophoresis 
as reported in Materials and Methods. In Figure 4A 
representative 2-DE gels of control, Au(NHC) and 
Figure 3: Apoptosis and modulation of cell signalling in A2780 cell line. (A) Percentage of apoptotic cells shown by flow 
cytometry analysis of annexin V/propidium iodide-stained A2780 cells treated for 72 h with Au(NHC) and Au(NHC)2 -72 h-exposure IC50-
dose. (B) Caspase-8, (C) Caspase-9 and (D) Caspase-3 activity shown by fluorescence-activated cell sorting analysis using FAM FLICA in 
A2780 cells treated for 72 h with Au(NHC) and Au(NHC)2 concentration corresponding to their 72 h-exposure IC50-dose. Flow cytometric 
images are representative of three independent experiments. Histograms report the mean values ±SD. The statistical analysis was carried out 
using one-way ANOVA test followed by Tuckey’s multiple comparisons test using Graphpad Prism v 6.0 (*p<0.05, **p<0.01, ***p<0.001).
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Au(NHC)2 -treated A2780 cells are shown. The 2-DE gel 
images were analysed by Progenesis SameSpots software 
4.0 (Nonlinear Dynamics, UK) using default parameters. 
After automatic spot detection, an average of about 1,500 
protein spots was detected in each gel. The computational 
2-DE gel image analysis pointed out 70 differentially 
expressed protein spots (ANOVA p-value≤0.05). In 
addition to univariate analysis (ANOVA test), multivariate 
analyses (q-value, PCA and power analysis) were 
performed to explore categories of differential protein 
expression. In detail, to reduce the expected level of 
false positives we performed a statistical analysis on the 
ANOVA p-values, by applying the false discovery rate 
correction method known as q-value, using Progenesis 
SameSpots software 4.0 [44]. To obtain an overview of 
the proteomic data for overall trends in carbene-treated 
and control cells a multivariate analysis by PCA was 
performed. Gels were grouped according to the variance 
of their protein spot expression. As shown in Figure 4B 
the first principal component, which distinguished 39% 
of the variance, clearly separates the proteome data of 
the mono and bis(carbene)-treated cells from control 
cells, and the second component, with additional 14% of 
the variance, distinguished between the two gold NHC 
complexes. Moreover, we calculated the power of our 
statistical analysis [45]. In our experiments, we achieved 
a target power of 87% confirming that the number of 
sample replicates used was appropriate. Finally, we 
considered as statistically different expressed the protein 
spots with an adjusted q-value≤0.1 and a power ≥0.8. 
Therefore, a statistically different expression level was 
found for 51 protein spots between the three cell lines. 
Afterwards, the ANOVA p-values have been submitted 
to Tukey post-hoc analysis for multiple comparison using 
GraphPad Prism 6.0 software. Comparisons between 
pairwise A2780 control cells, Au(NHC), and Au(NHC)2-
treated cells, revealed that the number of modulated spots 
was higher between controls and Au(NHC)2-treated cells 
(51 protein spots) (Figure 4C). Among these 51 protein 
spots, 19 were also significantly different between 
monocarbene and control cells showing the same trend 
as bis(carbene); six spots differed between Au(NHC) and 
Au(NHC)2-treated cells and finally only one protein spot 
varied between all the three conditions (Figure 4C and 
Table 2). In Supplementary Figure 3A–3E  histograms 
representing spot abundance variation between each 
treatment are reported. It is interestingly to note that, 
although not significant, the trend between control and 
Figure 4: Proteomic profile of Au(NHC) and Au(NHC)2-treated A2780 cells.  (A) Representative colloidal Coomassie blue 
silver-stained 2-DE gel images for control, Au(NHC) and Au(NHC)2-treated A2780 cells. Proteins (700 μg) were separated by 2-DE using 
IPG strips with a pH gradient of 3–10 non-linear and 9–16% linear gradient SDS-PAGE, as described in detail in Materials and Methods. 
Black circles and numbers indicate statistically differentially abundant protein spots, given as in Table 2. (B) Multivariate analysis of 
the 2-DE gel images results using Principal Components Analysis (PCA) performed by Progenesis SameSpots 4.0 software (Nonlinear 
Dynamic, UK). (C) Distribution of the differentially abundant protein spots between pairwise comparisons of control cells, Au(NHC)-
treated cells and Au(NHC)2-treated cells, as detected by 2-DE analysis.
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monocarbene-treated cells was always similar to that 
observed for bis(carbene) with the exception of the six 
spots that displayed the same trend as the control and thus 
resulted significant different from bis(carbene) treated 
cells.
The 51 statistically different expressed protein 
spots were subjected to Peptide Mass Fingerprint (PMF) 
analysis using MALDI TOF/TOF mass spectrometer and 
only those identifications with Mascot PMF score >56 
were considered significant (p-value<0.05). Such protein 
spots are highlighted with circles and numbers in the 
representative gels shown in Figure 4A. The results of 
PMF identification, together with the statistical analysis 
data, are reported in Table 2. When MS identification 
was successful, but with a low Mascot PMF score (≤70), 
the protein identification was confirmed by MALDI 
MS/MS analysis. The MS/MS results are summarized 
in Supplementary Table 1, in which the spot numbers 
correlate with those reported in Figure 4A and in Table 2.
As reported in Table 2, the experimental 
isoelectric point (pI) and molecular mass (Mr) values 
of the 51 identified proteins mostly matched with those 
theoretically predicted from the genome sequence. In 
some instances, the same protein was identified in spots 
that displayed a strong discrepancy between the observed 
position on 2-DE gels and the normal Mr, with a shift 
toward lower mass (e.g. spots 77, 44, 27, 28, 46, 67) 
suggesting the presence of protein fragmentation (Table 
2; Figure 4A).
The 51 identified proteins were classified into 
functional categories based on the Gene Ontology (GO) 
terms related to their major biological functions using 
UniProtKB database, v. 2017_02 released (http://www.
uniprot.org/). When proteins were associated with more 
than one function, one category was chosen arbitrarily. 
The most represented classes were those of protein 
synthesis (32%), metabolism (30%), cytoskeleton and 
cell structure (12%), stress response and chaperones 
(10%). The smaller functional classes are cell cycle and 
apoptosis (8%), DNA replication and repair (4%), cell 
redox homeostasis (2%) and transport (2%) (Figure 5A). 
To validate the proteomic result, we focused on proteins 
belonging to the most represented GO categories such 
as metabolism and cytoskeleton and cell structure. 
We measured, by western blot, the protein level of 
the glycolytic enzymes glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), aldolase A (ALDOA), triose 
phosphate isomerase1 (TPI1) and, the actin-modulating 
protein cofilin-1 (COF1). Consistent with 2-DE result, 
the protein level of GAPDH, ALDOA and TPI1 was 
higher in A2780 cells upon 24 h exposure to Au(NHC)2 
than in both controls and Au(NHC)-treated cells 
(Figure 5B). Likewise, the amount of COF1 resulted 
decreased both in mono-and in bis(carbene) treated cells 
(Figure 5B).
Overrepresentation enrichment analysis (ORA)
To provide insight into the cellular changes 
determined by Au(NHC), and Au(NHC)2 in A2780 human 
ovarian cancer cells, an overrepresentation enrichment 
analysis (ORA) of GO terms and pathways was carried out 
on the dataset generated from the identified proteins, using 
the web-accessible tool WebGestalt v. 2017 (WEB-based 
Gene SeT AnaLysis Toolket) (http://www.webgestalt.org). 
This method assesses the statistical overrepresentation of 
a user-defined, pre-selected gene/protein list of interest 
in a reference list of known gene/protein sets using a 
statistical test, e.g. the one-sided Fisher’s exact test or 
the hypergeometric distribution followed by multiple test 
adjustment using Benjamini-Hochberg correction (BH) 
[46–48]. Table 3  displays the statistically overrepresented 
GO terms and pathways (p-value≤ 0.1 after BH). A 
detailed composition and statistical parameters of each 
overrepresented GO term were reported in Supplementary 
Table 2. The GO Biological Processes (BP), enriched by 
the 51 identified proteins included ontologies involved 
in regulation of gene expression, nucleoside metabolic 
processes and in glycosyl compound metabolic process. 
We found also enriched the BP term “anatomical structure 
homeostasis” that indicates a homeostatic process involved 
in the maintenance of an internal steady-state of an 
organism, including control of cellular proliferation, death 
and control of metabolic function. Most of the top score 
Molecular Function (MF) GO terms belong to protein 
binding involved in cell adhesion, unfolded proteins, a 
ubiquitin-like protein ligase, RNA and telomeric DNA. 
Concerning Cellular Component (CC) GO terms, we found 
overrepresented the ontologies mitochondrial matrix, cell-
cell adherens junction and spliceosomal complex. The 
functional pathway analysis pointed out the enrichment of 
carbon metabolism and amino acid biosynthesis pathway, 
using KEGG database (www.kegg.jp), and of the pathway 
glycolysis using Panther database (www.pantherdb.org) 
(Table 3).
Influence of gold carbene complexes on cancer 
cell metabolism
Proteomic and bioinformatic data highlighted a 
pronounced cytotoxic effect mostly by Au(NHC)2 on cell 
energy metabolism. To strengthen these data, we evaluated 
the ability of these compounds to affect cellular glycolytic 
and mitochondrial activities. Therefore, we carried out an 
assessment of: i) glucose uptake, ii) oxygen consumption, 
iii) citrate synthase levels, iv) ATP levels and v) lactate 
production. A2780 cells were treated for both 24 and 48 h 
with mono or bis(carbene) at a concentration corresponding 
to their 72 h-exposure IC50-dose. In the first 24 h of 
treatment, there were no significant differences between 
carbene-treated and untreated cells (data not shown). After 
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Table 2: Differentially expressed protein spots identified by MALDI TOF/TOF mass spectrometry analysis
Spot
Noa
Protein name Gene
Name
ACb Observed Theorical Mascot search results A NOVA
p-valueg
FDRh Tukey’s post-hoc test i/ Average ratioj
Mr 
(kDa)/
pIc
Mr (kDa)/
pI
PMF
Scored
Matched
Pept.e
Seq.
coverage
(%)f
Au(NHC)
vs
CTR
Au(NHC)2
vs
CTR
Au(NHC)2
vs
Au(NHC) 
Stress Response and Chaperones
1 Heat shock 70 kDa 
protein 4
HSPA4 P34932 94.2/5.1 95.1/5.1 62k 7/15 11 0.030 0.081 ns (*) / 1.4 ns
2 Stress-70 protein, 
mitochondrial
HSPA9 P38646 63.0/5.2 73.9/5.9 62k 6/13 12 0.002 0.024 (**) / -1.6 (*) / -1.4 ns
3 T-complex protein 1 subunit 
zeta
CCT6A P40227 58.0/6.4 57.9/6.2 155 27/93 48 0.020 0.083 ns (*) / 1.5 ns
4 Stress-induced-
phosphoprotein 1
STIP1 P31948 46.0/6.6 45.9/6.6 177 32/86 51 0.03 0.082 ns (*) / -1.5 ns
5 Peptidyl-prolyl cis-trans 
isomerase A
PPIB P62937 16.4/7.6 18.2/7.7 79 11/55 50 0.0007 0.029 (*) / -1.2 (***) / -1.3 ns
Metabolism
(Glucose Metabolism)
6 Glyceraldehyde-3-
phosphate dehydrogenase
GAPDH P04406 37.2/7.6 36.2/8.6 109 13/23 40 0.0081 0.044 ns (**) / 1.5 ns
7 Fructose-bisphosphate 
aldolase A
ALDOA P04075 35.1/7.5 39.8/8.3 69k 8/26 29 0.005 0.035 ns (*) / 1.6 ns
8 Triosephosphate isomerase 
1
TPI1 P60174 26.2/6.2 31.1/5.6 92 7/18 36 0.007 0.040 ns (*) / 1.5 ns
9 UTP--glucose-1-phosphate 
uridylyltransferase
UGP2 Q16851 53.1/7.5 56.9/8.2 159 19p/64 25 0.034 0.083 ns (*) / -1.5 ns
(Cellular Respiration and ATP metabolism)
10 Aconitate hydratase, 
mitochondrial
ACO2 Q99798 81.6/7.2 86.1/7.4 90 10/30 22 0.0004 0.014 (**) / -1.4 (***) / -1.6 ns
11 Adenylate kinase 2, 
mitochondrial
AK2 P54819 28.9/7.5 26.7/7.7 62k 6/24 25 0.005 0.036 (*) / -1.3 (**) / -1.5 ns
12 Adenylate kinase 2, 
mitochondrial
AK2 P54819 28.9/7.6 26.7/7.7 62k 6/26 25 0.004 0.033 (*) / -1.4 (**) / -1.6 ns
13 ATP synthase subunit 
gamma, mitochondrial
ATP5C1 P36542 26.3/7.5 33.0/9.2 62k 6/28 15 0.003 0.081 (*) / -1.2 (**) / -1.4 ns
14 Cytochrome P450 4A22 CYP4A22 Q5TCH4 39.2/6.8 59.7/9.2 59k 7p/22 15 0.030 0.082 ns (*) / -1.2 ns
15 Transitional endoplasmic 
reticulum ATPase
VCP P55072 87.9/5.1 89.9/5.1 213 26/52 45 0.020 0.081 ns (*) / -1.4 ns
16 Transitional endoplasmic 
reticulum ATPase 
(fragment)
VCP P55072 35.6/5.5 89.9/5.1 74 9/38 15 0.030 0.085 ns (*) / 1.8 ns
(Folate Metabolism)
17 Bifunctional 
ethylenetetrahydrofolate 
dehydrogenase/
cyclohydrolase,
mitochondrial
MTHFD2 P13995 36.1/7.5 38.1/8.9 85 6/17 25 0.040 0.086 ns (*) / -1.5 ns
(Ketone Metabolism)
18 Succinyl-CoA:3-ketoacid 
coenzyme A transferase 1, 
mitochondrial
OXCT1 P55809 59.8/6.3 52.1/6.0 154 17/36 45 0.005 0.036 ns (**) / 1.6 (*) / 1.5
(Nucleotide Metabolism)
19 Deoxyuridine 
5’-triphosphate 
nucleotidohydrolase, 
mitochondrial
DUT P33316 20.1/5.7 26.8/9.5 72 6/21 34 0.00002 0.004 (***) / -1.7 (***) / -2.1 ns
(Amino-acid Metabolism)
20 3-hydroxyisobutyryl-CoA 
hydrolase, mitochondrial
HIBCH Q6NVY1 41.6/7.0 39.5/6.3 223 22/37 49 0.0024 0.036 ns (**) / -1.4 (*) / -1.3
(Continued )
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Protein synthesis
21 Elongation factor Tu, 
mitochondrial
TUFM P49411 44.7/6.6 49.9/7.3 73 6/12 17 0.0150 0.061 ns (*) / 1.5 ns
22 Elongation factor 2 
(fragment)
EEF2 P13639 28.5/6.5 95.2/6.4 107 22/67 25 0.001 0.021 ns (**) / 1.8 (*) / 1.4
23 Elongation factor 1-delta EEF1D P29692 39.2/4.7 31.2/4.9 58k 6/32 30 0.0134 0.081 (*) / -1.3 (*) / -1.4 ns
24 WD repeat-containing 
protein 61
WDR61 Q9GZS3 34.6/4.8 33.7/5.2 75 6/19 24 0.04 0.086 ns (*) / -1.4 ns
25 Heterogeneous nuclear 
ribonucleoprotein Q
SYNCRIP O60506 64.2/7.2 69.5/8.7 200 22/45 40 0.02 0.081 ns (*) / 1.8 ns
26 Heterogeneous nuclear 
ribonucleoprotein K
HNRNPK P61978 62.0/5.1 51.2/5.4 121 13/29 35 < 0.0001 0.011 (***) / -1.4 (****) / -1.6 ns
27 Heterogeneous nuclear 
ribonucleoprotein K
HNRNPK P61978 53.4/5.9 51.2/5.4 118 16/54 42 0.02 0.069 ns (*) / 1.4 ns
28 Heterogeneous nuclear 
ribonucleoprotein F
HNRNPF P52597 46.0/5.2 45.9/5.4 98 9/37 28 0.02 0.069 ns (*) / -1.6 ns
29 Heterogeneous nuclear 
ribonucleoprotein D0
HNRNPD Q14103 43.1/7.6 38.6/7.6 88 12/36 29 0.008 0.043 (*) / 1.6 (*) / 1.7 ns
30 Heterogeneous nuclear 
ribonucleoproteins A2/B1
HNRNPA2B1 P22626 32.2/7.4 37.5/8.9 66k 7/27 18 0.0009 0.021 (*) / 1.5 (***) / 1.8 ns
31 Heterogeneous nuclear 
ribonucleoprotein A1
HNRNPA1 P09651 32.2/7.6 38.8/9.2 142 17/58 32 0.0070 0.04 (*) / 2.2 (*) / 2.4 ns
32 RNA-binding protein 4 RBM4 Q9BWF3 42.2/6.6 40.7/6.6 108 9/22 36 0.0107 0.058 (*) / -1.3 (*) / -1.4 ns
33 Zinc finger protein 486 ZNF486 Q96H40 54.1/8.1 55.1/9.3 66k 8/28 22 0.019 0.067 ns (*) / 2.2 ns
34 Zinc finger protein 18 ZNF18 P17022 48.6/5.3 62.3/5.7 66k 8p/57 20 0.0007 0.029 ns (***) / 1.6 (**) / 1.5
35 Plasminogen activator 
inhibitor 1 RNA-binding 
protein
SERBP1 Q8NC51 54.1/8.6 45.0/8.7 66k 9/26 25 0.0207 0.069 ns (*) / 2.1 ns
36 N-myc (and STAT) 
interactor
NMI Q13287 25.4/5.9 35.2/5.2 77 8/21 26 0.044 0.089 ns (*) / -1.4 ns
Cytoskeleton and Cell Structure
37 Proliferation-associated 
protein 2G4
PA2G4 Q9UQ80 45.6/6.3 44.1/6.1 95 8/18 28 0.0159 0.060 ns (*) / -1.5 (*) / -1.5
38 Nucleophosmin NPM1 P06748 41.1/4.6 32.7/4.6 94 11/40 31 0.0002 0.012 (*) / -1.4 (***) / -2.5 (*) / -1.8
39 Mitogen-activated protein 
kinase kinase kinase MLT 
(fragment)
ZAK Q9NYL2 23.1/7.3 91.2/7.9 60k 9/41 17 0.0370 0.086 ns (*) / 1.4 ns
40 26S protease regulatory 
subunit 10B
PSMC6 P62333 43.4/7.3 44.4/7.1 198 23/35 58 0.0370 0.086 ns (*) / -1.2 ns
41 Tubulin beta chain TUBB P07437 36.6/5.3 50.1/4.8 72 6/15 21 0.0040 0.033 (*) / -1.4 (**) / -1.6 ns
42 F-actin-capping protein 
subunit alpha-1
CAPZA1 P52907 36.4/5.3 33.1/5.4 96 6/8 34 0.035 0.082 ns (*) / -1.2 ns
43 Tropomyosin alpha-3 chain TPM3 P06753 33.2/4.6 32.9/4.7 70k 6/16 14 0.024 0.072 ns (*) / -1.3 ns
44 Cofilin-1 COF1 P23528 17.4/6.4 18.7/8.2 122 11/43 68 0.0005 0.019 (**) / -3.1 (***) / -4.3 ns
45 Cytoskeleton-associated 
protein 2 (fragment)
CKAP2 Q8WWK9 23.2/9.6 77.5/9.5 81 14/32 18 0.0035 0.031 (*) / 1.5 (**) / 1.6 ns
46 Vascular cell adhesion 
protein 1 (fragment)
VCAM1 P19320 31.9/5.2 82.3/5.1 63k 6/15 16 0.034 0.036 ns (**) / 1.7 (*) / 1.4
Cell redox homeostasis
47 Peroxiredoxin-1 PRDX1 Q06830 23.7/7.5 22.3/8.3 79 7/40 52 0.016 0.049 (*) / -1.3 (*) / -1.4 ns
Transport
48 Voltage-dependent anion-
selective channel protein 2
VDAC2 P45880 33.3/7.3 32.1/7.5 75 6/20 35 0.0032 0.030 (**) / 1.4 (**) / 1.4 ns
(Continued )
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48 h, all four parameters showed an evident change only in 
Au(NHC)2-treated cells whereas monocarbene was slightly 
less effective. Even if, both gold complexes gave rise to a 
significant decrease of glucose uptake (Figure 6A), only 
the bis(carbene) turned out to be an inhibitor of respiration. 
Indeed, in Au(NHC)2-treated cells the oxygen consumption 
diminished of 1.7-fold in comparison with Au(NHC) and 
control cells (Figure 6B). Remarkably, upon Au(NHC)2 
exposure, the amount of citrate synthase (CS), the rate-
limiting enzyme of TCA cycle, was lower compared with 
control cells, showing a decrease of about 2-fold (Figure 
6C). In line with the observed slowdown of mitochondrial 
respiration, the ATP level was reduced of about 2.8-fold 
(Figure 6D); conversely, the lactate production was increased 
of about 1.9-fold in bis(carbene)-treated cells (Figure 6E).
Interference with cellular redox homeostasis
Mitochondria and the oxidative phosphorylation 
pathway have already been identified as primary cellular 
targets for auranofin and several NHC gold complexes 
through inhibition of the seleno-enzyme thioredoxin 
reductase (TrxR) [26, 35–37, 40]. Indeed, TrxR is 
an essential antioxidant enzyme for maintaining the 
intracellular redox homeostasis and is involved in cell 
growth and survival. Its inhibition leads to an increase of 
cellular ROS, an impairment of mitochondrial functions, 
and finally to apoptosis [26]. Within this frame, we 
evaluated whether the antiproliferative effects of Au(NHC) 
and Au(NHC)2 complexes in A2780 cells could be 
explained by direct inhibition of TrxR. The enzyme activity 
was assessed on protein extracts obtained from A2780 cells 
treated, for 24 h, with each carbene complex IC50-dose. 
Notably, both gold carbenes inhibited TrxR (Figure 7A). 
The most effective compound was Au(NHC)2 causing about 
50 percent inhibition of enzyme activity, whereas Au(NHC) 
caused a smaller reduction (ca. 25 percent). On the ground 
of these results, we evaluated whether the inhibitory effect 
on TrxR could lead to ROS formation and changes of the 
mitochondrial membrane potential (Δψm). The influence of 
carbene complexes on the cellular reactive oxygen species 
(ROS) levels were investigated in time course experiments 
(12, 24, 48 and 72 h after treatment) using the fluorogenic 
dye H2DCFDA in conjunction with flow cytometer. In this 
case, both drugs were unable to rise cellular ROS. Figure 7B 
shows the results 72 h after treatment. We further assessed 
the production of the superoxide anion, the predominant 
ROS species in mitochondria, using the fluorogenic dye 
MitoSOX Red specifically targeted to mitochondria, 
and flow-cytometry. We performed the same time course 
experiments and we observed that only Au(NHC)2 led to a 
2.5-fold increase of mitochondrial ROS production after 72 
h of treatment (Figure 7C). Since increase of mitochondrial 
ROS may be initiated by dysfunctional mitochondria 
[49], we analysed by flow-cytometry the mitochondrial 
membrane potential (Δψm), on the same treated-cells, using 
the cyanine dye DiIC1(5) (Figure 7D). In line with the data 
on mitochondrial superoxide anion levels, this experiment 
pointed out that only Au(NHC)2 affected the Δψm and after 
72 h of exposure. Indeed, we observed in Au(NHC)2 a 2.8-
fold increase of cells with lower Δψm values in comparison 
with both control and monocarbene-treated cells.
Au(NHC) and Au(NHC)2 induce antiproliferative 
effects in other human ovarian cancer cell lines
To strengthen the data achieved up to now on 
carbene antiproliferative mechanisms in A2780 cells we 
carried out confirmatory experiments on other human 
ovarian cancer cell lines. We tested IGROV1 and SKOV3 
established human ovarian cancer cell lines that constitute 
relevant in vitro tumor models, for ovarian cancer 
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49 Oxysterol-binding protein-
related protein 1 (fragment)
OSBPL1A Q9BXW6 46.1/4.7 109.8/5.9 57k 7/13 8 0.005 0.035 ns (**) / 2 ns
DNA replication and repair
50 RuvB-like 1 RUVBL1 Q9Y265 53.4/6.4 50.2/6.0 269 30/63 61 0.0220 0.091 ns (*) / -1.4 ns
51 Single-stranded 
DNA-binding protein, 
mitochondrial
SSBP Q04837 15.2/8.2 17.2/9.6 70k 6/23 37 0.0122 0.067 ns (**) / 1.5 ns
a Spot numbers match those reported in the representative 2-DE images shown in Figure 4A.
b Accession number in Swiss-Prot/UniProtKB (http://www.uniprot.org/).
c Observed Mr/pI, based on the calculation using Progenesis SameSpots 4.0 software
d MASCOT MS score (Matrix Science, London, UK; http://www.matrixscience.com). MS matching score greater than 56 was required for a significant MS hit (p-value<0.05).
e Number of matched peptides correspond to peptide masses matching the top hit from Ms-Fit PMF, searched peptides are also reported.
f Sequence coverage = (number of the identified residues/total number of amino acid residues in the protein sequence) x100%.
g ANOVA test was performed by Progenesis SameSpots 4.0 software to determine if the relative change was statistically significant (p<0.05).
h q-value is a False Discovery Rate adjusted p-value (FDR) and it was calculated by Progenesis SameSpots 4.0 software in order to establish how many of the significant ANOVA p-values were false 
positives. Only the protein spots with a q-value<0.1 were considered for the mass spectrometry analysis.
i Tukey’s post-hoc test was performed on ANOVA p-values by GraphPad Prism 6.0 software (*p<0.05), (**p<0.01), (***p<0.001), (****p<0.0001), (ns= not significant).
j Average ratio was calculated by GraphPad Prism 6.0 software. It is the ratio between the mean normalized spot volumes of A2780 control cells (CTR), A2780 cells treated with Au(NHC) and A2780 cells 
treated with Au(NHC)2. (Volume e=integration of the optical density over the spot area; %V = V single spot/V total spots included in the reference gel by Progenesis SameSpots 4.0 software).
k Protein spots with a Mascot PMF score ≤70. These spots were subjected to MS/MS analysis to confirm the PMF identification. The results are reported in Supplementary Table 2.
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research. IGROV1 cell line was established from an 
ovarian endometrioid adenocarcinoma, whereas SKOV3 
cell line derived from ascitic fluid from a caucasian female 
with an ovarian tumour. As confirmatory experiments, we 
decided to evaluate: i) the cytotoxicity of the two gold 
carbenes against the two above mentioned tumor cell 
lines and the apoptotic cell death, ii) their influence on 
cell metabolism and, iii) the inhibitory potential toward 
TrxR. The cytotoxic effects of these gold(I) complexes 
were evaluated on IGROV1 and SKOV3 cell lines by 
the MTT proliferation assay and compared with those of 
cisplatin (Table 4). After a 72h exposure, both carbenes 
were more active than cisplatin (6.1 μM) against SKOV3 
cells although Au(NHC)2 was highly more cytotoxic (0.5 
μM) than Au(NHC) (4.7 μM). As far as the IGROV1 cell 
line is concerned, the following cytotoxic activity was 
observed: Au(NHC)2 > cisplatin > Au(NHC) (i.e. ca. 0.4, 
1.2, 3.9 μM, respectively). Thus, different antiproliferative 
effects of the study gold carbenes on SKOV3 and 
IGROV1 are in agreement with findings achieved in 
A2780 cells. Afterwards, we examined if Au(NHC) and 
Au(NHC)2 also lead to apoptotic cell death in IGROV1 
and SKOV3 cells. We performed flow cytometry analysis 
of annexin V/propidium iodide-stained cells treated 
with Au(NHC) or Au(NHC)2 72 h- IC50-dose, for 72 h. 
Surprisingly, the cell-state distribution highlighted a 
pronounced antiproliferative effect in both cell line only 
by Au(NHC)2. As shown in Figure 8, about 40% of late 
apoptotic IGROV1 cells (Figure 8A) and about 30% 
SKOV3 cells (Figure 8B) were  present in bis(carbene)-
treated cells. The monocarbene-treated cells behaved like 
controls (Figure 8A and 8B).
To evaluate the influence of Au(NHC) and 
Au(NHC)2 on IGROV1 and SKOV3 cellular glycolytic 
and mitochondrial metabolism, we analysed: i) the level 
of some glycolytic enzymes pointed out by proteomic 
analysis on A2780 cells, ii) the level of the citrate 
synthase, iii) the lactate production and iv) the oxygen 
consumption. Cells were treated for both 24 and 48 h with 
the mono or bis(carbene) 72 h-exposure IC50-dose. In line 
with the data on A2780 cells, in the first 24 h of treatment, 
we detected a significant change only in the glycolytic 
enzyme levels (Figure 9A), whereas all other parameters 
showed an evident difference just after 48 h of treatment 
(Figure 9B and Figure 10). Specifically, the western blot 
analysis on the glycolytic enzymes GAPDH, ALDOA and 
TPI1 highlighted an increased level only in bis(carbene) 
IGROV1 and SKOV3-treated cells (Figure 9A). Besides, 
only Au(NHC)2 gave rise to a decrease in the amount of 
the TCA cycle key enzyme CS (Figure 9B). We found 
a decrease of about 1.4-fold in IGROV1 cells and of 
about 1.2-fold in SKOV3 cells. In any case the behaviour 
of Au(NHC)-treated cells was similar to controls 
(Figure 9). Consistent with the increment of glycolytic 
enzyme level, we found that the lactate production was 
increased in bis(carbene)-treated cells (Figure 10A). In 
IGROV1, we detected a lactate production of about 2-fold 
higher respect to controls and in SKOV3 of about 1.8-
fold (Figure 10A). This enhancement in lactate production 
was accompanied in Au(NHC)2-treated cells by a slight 
slowdown of oxygen consumption. Indeed, in IGROV1 
cells we observed a respiration reduction of about 1.3-
fold respect to controls and in SKOV3 of about 1.2-fold 
(Figure 10B). Overall, the monocarbene complex did not 
lead to significant changes in both lactate production and 
oxygen consumption (Figure 10A and 10B).
Even if, only the bis(carbene) complex gave rise to 
significant changes in cell metabolism, both Au(NHC) 
and Au(NHC)2 turned out to be inhibitors of TrxR activity 
(Figure 11). The TrxR enzymatic assay pointed out that 
after 24 h of Au(NHC) treatment the enzyme activity was 
reduced of about 25% in IGROV1 cells and about 23% 
in SKOV3. The bis(carbene) showed a greater inhibitory 
potential triggering a reduction in TrxR activity of about 
48% in IGROV cells and of about 44% in SKOV3 cells 
(Figure 11).
DISCUSSION
Cytotoxicity, logP, cell cycle alterations and cell 
death
In the present work, we sought to investigate 
the cytotoxic effects and the associated proteomic 
alterations of two new gold(I)-N-heterocyclic carbene 
complexes, namely Au(NHC) and Au(NHC)2, in A2780 
human ovarian cancer cells. Valuable antiproliferative 
effects were observed for both carbene complexes, but 
to different degrees, with Au(NHC)2 being more active 
than the monocarbene. This higher cytotoxicity of the 
bis(carbene) was accompanied by a cell cycle arrest with 
a significant accumulation of cells in the G1 phase whereas 
the monocarbene did not induce any specific phase arrest. 
However, both mono and bis(carbene) treatments led to 
cell death via apoptosis. In determining whether caspase 
cascade was involved the in cell death process, we 
observed that both Au(NHC) and Au(NHC)2 triggered a 
significant activation of caspase-8 whereas caspase-9 and 
caspase-3 displayed an increase only with the bis(carbene). 
Caspase-8 and caspase-9 are initiator caspases of the 
extrinsic and the intrinsic apoptotic pathway, respectively. 
These data indicated, for the monocarbene, a cell death 
mediated by the extrinsic apoptotic pathway and, for 
the bis(carbene) an involvement of both extrinsic and 
intrinsic apoptotic pathways. It is noteworthy that, 
besides the lower lipophilicity compared to monocarbene, 
the bis(carbene) displayed a greater cytotoxicity and, 
properties like those observed in delocalized lipophilic 
cations (DLCs) [50], could be expected for Au(NHC)2. As 
a matter of fact, in the scientific literature several examples 
of charged complexes as DLCs have been reported that 
are able to accumulate inside mitochondria, penetrating 
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the hydrophobic barrier of the cellular membranes due 
to the electric gradient between membranes’ inner and 
outer layers [51]. All these findings suggested, in terms 
of structure–activity relationships, that the introduction 
of the second carbene ligand in Au(NHC)2 enhanced the 
antiproliferative effects of gold NHC center [52, 53]. 
This trend of increasing cytotoxicity when substituting a 
chloride with a phosphane or NHC ligand has previously 
been observed for other gold (I)-NHC complexes [35, 
54]. In part, this has been associated to the formation 
of cationic species [Au(NHC)2]
+ which might induce 
mitochondrial accumulation and improve cytotoxic effects 
[32, 55, 56].
Proteomic results and affected proteins
To identify proteins involved in the antiproliferative 
effects of the Au(NHC) and Au(NHC)2 in A2780 cells, a 
comparative proteome study using 2-DE and MS based 
analysis has been carried out. The results pointed out 51 
differentially expressed proteins. In line with the cytotoxic 
properties of the two gold carbene compounds, the number 
of modulated protein spots was higher in Au(NHC)2-
treated cells and lower in Au(NHC)-treated cells. It is 
noteworthy that the 19 modulated proteins highlighted in 
monocarbene-treated cells varied with the same trend in 
bis(carbene)-treated cells. In addition, only six proteins 
differed between Au(NHC) and Au(NHC)2-treated 
cells, showing the same tendency both in control and in 
monocarbene-treated cells.
All the 51 modulated proteins play specific roles in 
a variety of biological processes. Most of them belong to 
GO functional classes i.e. protein synthesis, metabolism, 
cytoskeleton and cell structure, stress response and 
chaperones. To understand the biological meaning 
behind the list of the identified proteins, we analysed 
them by the functional enrichment analysis web tool 
WebGestalt. We found statistically enriched the BP term 
Figure 5: Functional classification of the identified proteins and validation of proteomic results. (A) The identified proteins 
were classified based on the Gene Ontology (GO) terms related to their major biological functions using UniProtKB database (http://
www.uniprot.org/). Several proteins were associated with more than one function, and in such case, one category was chosen arbitrarily. 
(B) Validation of some identified proteins belonging to the most represented GO categories (metabolism; cytoskeleton and cell structure). 
Western blot analysis of the glycolytic enzymes GAPDH, ALDOA, TPI1 and the actin-modulating protein COF1 in A2780 cells upon 24 
h-exposure to Au(NHC) and Au(NHC)2. Representative Immunoblots are shown together with the corresponding Coomassie-stained PVDF 
membranes. Histogram reports normalized mean relative-integrated-density ± SD values of the GAPDH, ALDOA, TPI1 and COF1 bands. 
The statistical analysis was carried out using one-way ANOVA test followed by Tuckey’s multiple comparisons test using Graphpad Prism 
v 6.0 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
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Table 3: Overrepresentation Enrichment Analysis (ORA) of GO terms and pathways obtained from the identified 
protein list, using Webgestalt functional enrichment analysis web tool
Gene set Description Ca Ob Ec Rd p-valuee FDRf
Biological Process
GO:0010608 posttranscriptional regulation 
of gene expression
454 10 1.35 7.40 6.29E-07 4.79E-04
GO:0034248 regulation of cellular amide 
metabolic process
359 8 1.07 7.49 9.00E-06 3.43E-03
GO:0071897 DNA biosynthetic process 194 6 0.58 10.4 2.17E-05 5.52E-03
GO:0009123 nucleoside monophosphate 
metabolic process
308 7 0.92 7.64 3.09E-05 5.89E-03
GO:0006091 generation of precursor 
metabolites and energy
365 7 1.09 6.44 9.04E-05 1.38E-02
GO:0046939 nucleotide phosphorylation 90 4 0.27 14.9 1.44E-04 1.83E-02
GO:0009141 nucleoside triphosphate 
metabolic process
290 6 0.86 6.95 2.01E-04 2.08E-02
GO:1901657 glycosyl compound 
metabolic process
421 7 1.25 5.58 2.19E-04 2.08E-02
GO:0009132 nucleoside diphosphate 
metabolic process
109 4 0.32 12.3 3.01E-04 2.55E-02
GO:0060249 anatomical structure 
homeostasis
341 6 1.02 5.91 4.80E-04 3.66E-02
Molecular Function
GO:0098631 protein binding involved in 
cell adhesion
293 7 0.99 7.00 5.27E-05 1.26E-02
GO:0050839 cell adhesion molecule 
binding
445 8 1.52 5.27 1.08E-04 1.26E-02
GO:0042162 telomeric DNA binding 30 3 0.10 29.3 1.40E-04 1.26E-02
GO:0051082 unfolded protein binding 105 4 0.36 11.2 4.35E-04 2.92E-02
GO:0003727 single-stranded RNA binding 70 3 0.24 12.6 1.72E-03 9.08E-02
GO:0017025 TBP-class protein binding 21 2 0.07 27.9 2.29E-03 9.08E-02
GO:0003729 mRNA binding 170 4 0.58 6.89 2.60E-03 9.08E-02
GO:0044389 ubiquitin-like protein ligase 
binding
285 5 0.97 5.14 2.70E-03 9.08E-02
GO:0042287 MHC protein binding 25 2 0.08 23.4 3.24E-03 9.43E-02
GO:0036002 pre-mRNA binding 26 2 0.08 22.5 3.51E-03 9.43E-02
Cellular Component
GO:0043209 myelin sheath 165 7 0.62 11.3 2.11E-06 3.12E-04
GO:0005759 mitochondrial matrix 423 8 1.59 5.04 1.33E-04 7.27E-03
GO:0005913 cell-cell adherens junction 318 7 1.19 5.87 1.47E-04 7.28E-03
GO:0009295 nucleoid 45 3 0.17 17.8 6.16E-04 2.28E-02
GO:0005681 spliceosomal complex 173 4 0.65 6.16 3.81E-03 1.00E-01
(Continued )
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posttranscriptional regulation of gene expression. This 
GO term included 6 proteins of the hnRNP (heterogeneous 
nuclear ribonucleoproteins) family that comprises 
multifunctional proteins participating in a variety of 
cellular processes related to mRNA splicing, stability 
and transport to the cytoplasm. Given their central roles 
in the regulation of gene expression, deregulation of 
individual hnRNPs was involved in tumour development 
and progression, including inhibition of apoptosis, 
angiogenesis and cell invasion [57]. Moreover, hnRNP 
proteins significantly affect responses to chemotherapy, 
acting as mediators or modulators of drug-induced 
apoptosis [58]. However, the pathomechanisms of many 
hnRNPs remain to be elucidated [59]. In the current study 
the subtypes Q, D, A2/B1, A1 and an isoform of K were 
upregulated whilst the subtypes F and another isoform 
of K were downregulated in bis(carbene) treated cells. 
The monocarbene affected, with the same trend, only 
the subtypes D, A2/B1, A1 and an isoform of K. Since 
products of alternative splicing often possess different, 
even opposite functions, the change of abundance patterns 
is likely to play a significant role in the early cellular 
response to drug treatment [57, 59]. Further investigations 
are required to strengthen their involvement in carbene 
antiproliferative effects. In the enriched GO term 
posttranscriptional regulation of gene expression, we 
found also the phosphoprotein nucleophosmin (NPM1) 
mainly localized at nucleoli. This protein belongs 
to a histone chaperones family, the Nucleophosmin/
nucleoplasmin (NPM) family, and has an important 
role in several pathways including mRNA transport, 
chromatin remodeling, apoptosis, and regulation of tumor 
suppressors p53/TP53 and ARF [60]. Nucleophosmin is 
frequently overexpressed in tumours. Previous studies 
showed that NPM1 is downregulated in cancer cells 
during drug-induced apoptosis [61, 62]. Our finding 
that both carbene complexes induced a downregulation 
of NPM1, as other anticancer drugs mentioned above, 
suggested a direct or indirect involvement of this protein 
in the apoptotic process in A2780 cells.
The functional enrichment analysis highlighted 
also the overrepresentation of GO BP terms and 
pathways related to carbon metabolism and glycolysis. 
These GO categories comprise the glycolytic enzymes 
GAPDH, ALDOA and TPI1 that were upregulated only 
in Au(NHC)2 treated cells. Conversely, the amount of 
several enzymes involved in cellular respiration and ATP 
production decreased with both carbenes (i.e. ACO2, AK2, 
ATP5C1) and some of them only with bis(carbene) (i.e. 
CYP4A22 and VCP). These data suggested a possible 
effect of Au(NHC)2 on cell energy metabolism. To 
strengthen these data, we evaluated the cellular glycolytic 
and mitochondrial activity measuring: i) glucose uptake, 
ii) oxygen consumption, iii) citrate synthase levels, iv) ATP 
levels and v) lactate production. The obtained results were 
in line with the high cytotoxic potency of bis(carbene) 
complex. Indeed, after 48 h, all four parameters showed 
an evident change in Au(NHC)2-treated cells whereas 
monocarbene was slightly less effective. While, both 
mono and bis(carbene) complexes induced a significant 
decrease of glucose uptake, mostly Au(NHC)2 elicited a 
strong inhibition of respiration coupled with a decrease 
of citrate synthase (CS) amount, the rate-limiting enzyme 
of TCA cycle. In Au(NHC)2-treated cells, this impairment 
of respiration and the dysfunctional TCA cycle were 
accompanied by a lower ATP content. The lactate 
production, in turn, was enhanced, suggesting a glycolysis 
acceleration. Thus, the decrease of oxygen consumption 
and the increase of lactate production reflected the ability 
of Au(NHC)2 to impair respiration and to determine a 
metabolic shift towards glucose fermentation probably as 
a compensatory mechanism. In this analysis, mitochondria 
appeared to be a cellular target mostly of bis(carbene) 
compound.
Among the six differentially expressed proteins 
between the two carbene complexes, we found two 
proteins involved in cell metabolism: OXCT1, the key 
enzyme for ketone body catabolism that increased in 
bis(carbene)-treated cells and the protein HIBCH involved 
in the pathway amino-acid degradation that decreased 
Gene set Description Ca Ob Ec Rd p-valuee FDRf
Pathways (KEGG database)
hsa01200 Carbon metabolism 114 5 0.49 10.2 1.13E-04 3.43E-02
hsa01230 Biosynthesis of amino acids 75 4 0.32 12.3 2.80E-04 4.24E-02
Pathways (Panther database)
P00024 Glycolysis 17 3 0.08 36.5 5.50E-05 6.22E-03
a The number of reference genes in the category
b The number of genes in the user gene list and also in the category
c The expected number in the category
d Ratio of enrichment
e p-value from hyergeometric test
f FDR from Benjamini and Hochberg (BH).
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respect to both controls and monocarbene treated cells. 
We found also two proteins involved in the GO category 
protein synthesis: the elongation factor 2 (EEF2) 
identified as a fragment and the zinc finger protein 18, 
both increased in bis(carbene)-treated cells. Two proteins 
belong to the GO category cytoskeleton and cell structure 
such as the vascular cell adhesion protein VCAM1, 
identified as a fragment that increased after bis(carbene) 
exposure and the proliferation-associated protein 2G4 
(PA2G4) involved in growth regulation that conversely 
decreased. The meaning of the six differentially expressed 
proteins between the mono- and bis(carbene) remains to 
be clarified. In this regard, we must investigate deeply 
the role of the two gold carbenes in the GO biological 
processes to which the six proteins belong (protein 
synthesis, cytoskeleton etc.).
Thioredoxin reductase as a target
The seleno-enzyme thioredoxin reductase (TrxR) 
is an essential antioxidant enzyme for maintaining the 
intracellular redox homeostasis and is involved in cell 
growth and survival. Its inhibition leads to an increase of 
cellular ROS, an impairment of mitochondrial functions, 
Figure 6: Influence of gold carbene complexes on cancer A2780 cell metabolism.  A2780 cells were treated with Au(NHC) and 
Au(NHC)2 for 48 h with their 72 h-exposure IC50-dose (A) Glucose uptake was assessed using 1μCi 2-deoxy-D-2-3H-glucose (1mCi/0.1 
mmol) as described, in detail, in Materials and Methods section. (B) Oxygen consumption was measured using a Clark-type O2 electrode 
from Hansatech. (C) Western blot analysis of citrate synthase (CS). Representative Immunoblots are shown together with the corresponding 
Coomassie-stained PVDF membranes. Histogram reports normalized mean relative-integrated-density ± SD values of the CS bands. (D) 
Lactate amount was detected in one millilitre of medium supernatant using a commercial L-lactic acid Assay Kit (Megazyme). (E) ATP 
amount was assessed with ATP Determination Kit (Molecular Probes) according to manufacturing instruction. Histograms report the mean 
values ±SD of at least three independent experiments. The statistical analysis was carried out using one-way ANOVA test followed by 
Tuckey’s multiple comparisons test using Graphpad Prism v 6.0 (*p<0.05, **p<0.01, ****p<0.0001).
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and finally to apoptosis. Since TrxR had already been 
identified as an important target of several gold(I) 
complexes (i.e. auranofin, gold(I) NHC complexes) [26, 
35–38], the mono and bis(carbene) complexes were tested 
for their ability to inhibit TrxR in A2780 treated cells. Both 
gold compounds gave rise early (after 24 h) to inhibition 
of TrxR, but the most potent inhibitor was Au(NHC)2, 
correlating well with its higher cytotoxic effects with 
respect to the monocarbene. On the ground of these results, 
we evaluated whether the inhibitory effect on TrxR could 
lead to ROS formation and alteration of the mitochondrial 
membrane potential (Δψm). Unexpectedly, in both mono 
and bis(carbene)-treated cells, the TrxR inhibition was 
not followed by an accumulation of cytosolic ROS, 
even after 72 h of exposure, indicating that generalised 
oxidative stress is not responsible for the observed 
events. However, in bis(carbene) treated cells we found 
an increase of mitochondrial superoxide associated with a 
Figure 7: Interference with cellular redox state in A2780 cells. A2780 cells were treated with Au(NHC) and Au(NHC)2-72 
h-IC50-dose. (A) TrxR enzyme inhibition assay was performed after 24 h of treatment using a commercial thioredoxin reductase assay kit 
(Sigma-Aldrich). (B) Cellular generic ROS production were evaluated after 72 h of treatment by the fluorogenic dye H2DCFDA analysed 
using a fluorescence spectrophotometer. (C) Mitochondrial superoxide anion production was assessed using the fluorogenic dye MitoSOX 
Red production by flow cytometry after 72 h of treatment. (D) Mitochondrial membrane potential (Δψm) using the cyanine dye DiIC1(5) 
and flow cytometry, after 72 h of treatment. Flow cytometric images are representative of three independent experiments. Histograms report 
the mean values ±SD. The statistical analysis was carried out using one-way ANOVA test followed by Tuckey’s multiple comparisons test 
using Graphpad Prism v 6.0 (*p<0.05, **p<0.01, ***p<0.001).
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decrease Δψm. These findings further reinforced the view 
that the mitochondrial pathways are primarily involved in 
Au(NHC)2-dependent proapoptotic effects, most likely in 
relation to selective inhibition of thioredoxin reductase. 
On the other hand, a direct involvement of oxidative stress 
could be ruled out since mitochondrial ROS production 
and membrane depolarization can be detected only after 
72 h, when the apoptosis pathway was already started. 
Thus, it is likely that ROS initiated from dysfunctional 
mitochondria instead of being the primary cause of the 
Au(NHC)2 cytotoxic effects. Likewise, Rigobello et al. 
demonstrated that, in Jurkat T cells, gold(I) complexes 
(auranofin and TepAu) induced apoptosis through 
inhibition of TrxR but with limited oxidative stress [63].
Thioredoxin is the main substrate of TrxR. 
Inhibition of TrxR activity led to the decrease of reduced 
(active) form of thioredoxin triggering an unbalance of 
cell redox state [64]. It is noteworthy that, besides its 
direct role in regulating cellular ROS level, thioredoxin 
controls the redox state of several proteins involved 
in different redox-signaling pathways. For example, 
thioredoxin has a direct interaction with the apoptotic 
pathway through the negative regulator ASK1 as well as 
through the phosphatase and tensin homolog (PTEN) [65, 
66]. Therefore, our data seems to suggest that, instead of a 
direct role in ROS production, the Au(NHC)2 cytotoxicity 
could mainly affect, through TRxR inhibition, molecular 
targets involved in redox-signalling pathways.
Table 4: Antiproliferative effects of Au(NHC), Au(NHC)2 and cisplatin on cell growth of SKOV3 and IGROV1 
ovarian cancer cells after 72 h drug exposure
IC50 (μM) ± SD
Au(NHC) Au(NHC)2 Cisplatin
SKOV3 4.708±0.842 0.552±0.044 6.111±1.098
n 3 3 3
IGROV1 3.922±0.533 0.387±0.057 1.170±0.177
n 3 3 3
n, number of independent experiments; SD, standard deviation.
Figure 8: Apoptosis induction in IGROV1 and SKOV3 ovarian cancer cells. Percentage of apoptotic cells shown by flow 
cytometry analysis of annexin V/propidium iodide-stained IGROV1 (A) and SKOV3 (B) cells treated for 72 h with Au(NHC) and 
Au(NHC)2-72 h-exposure IC50-dose. Flow cytometric images are representative of three independent experiments. Histograms report the 
mean values ±SD. The statistical analysis was carried out using one-way ANOVA test followed by Tuckey’s multiple comparisons test 
using Graphpad Prism v 6.0 (**p<0.01).
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Antiproliferative effects in other human ovarian 
cancer cell lines
Ovarian cancer is a morphologically and biologically 
heterogeneous disease and therapeutic approaches need to 
account for inter-patient and intra-tumoural heterogeneity. 
We have therefore decided to confirm the cytotoxic 
activity of the two gold carbenes in established cell lines 
derived from other human ovarian neoplasms such as 
IGROV1 and SKOV3 cells that are commonly used for 
in vitro studies in ovarian cancer research. The IC50 values 
and the analysis of apoptosis revealed a slightly lower 
Figure 9: Effects of carbenes on the level of selected glycolytic and mitochondrial enzymes in IGROV1 and SKOV3 
cells. Western blot analysis of the glycolytic enzymes GAPDH, ALDOA, TPI1 (A) and of the mitochondrial enzyme CS (B) in IGROV1 
and in SKOV3 cells upon exposure to Au(NHC) and Au(NHC)2. Representative Immunoblots are shown together with the corresponding 
Coomassie-stained PVDF membranes. Histogram reports normalized mean relative-integrated-density ± SD values of the GAPDH, ALDOA, 
TPI1 and CS bands. The statistical analysis was carried out using one-way ANOVA test followed by Tuckey’s multiple comparisons test 
using Graphpad Prism v 6.0 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
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Figure 10: Influence of gold carbene complexes on cancer IGROV1 and SKOV3 cell metabolism. IGROV1 and SKOV3 
cells were treated with Au(NHC) and Au(NHC)2 for 48 h with their 72 h-exposure IC50-dose (A) Lactate amount was detected in one 
millilitre of medium supernatant using a commercial L-lactic acid Assay Kit (Megazyme); (B) Oxygen consumption was measured using a 
Clark-type O2 electrode from Hansatech. (For details, see Materials and Methods). Histograms report the mean values ±SD of at least three 
independent experiments. The statistical analysis was carried out using one-way ANOVA test followed by Tuckey’s multiple comparisons 
test using Graphpad Prism v 6.0 (*p<0.05, **p<0.01, ***p<0.001).
Figure 11: Inhibition of TrxR by carbenes in IGROV1 and SKOV3 cells.  IGROV1 and SKOV3 cells were treated with 
Au(NHC) and Au(NHC)2-72 h-IC50-dose. TrxR enzyme inhibition assay was performed after 24 h of treatment, using a commercial 
thioredoxin reductase assay kit (Sigma-Aldrich), in (A) IGROV1 and (B) SKOV3 cells. For details, see Materials and Methods. Histograms 
report the mean values ±SD. The statistical analysis was carried out using one-way ANOVA test followed by Tuckey’s multiple comparisons 
test using Graphpad Prism v 6.0 (***p<0.001, ****p<0.0001).
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cytotoxicity for both mono and bis(carbene) compounds 
in these cell lines respect to A2780 cells. However, the 
greater activity of Au(NHC)2 compared to Au(NHC) was 
confirmed. In fact, only Au(NHC)2 triggered apoptotic 
cell death both in IGROV1 and in SKOV3, with SKOV3 
showing more resistance. This trend has also occurred 
analysing the carbene influence on cell metabolism. 
The results pointed out that only the bis(carbene) led 
to enhancement of lactate production coupled with a 
slowdown of respiration in both IGROV1 and SKOV3 
cell lines. These data were also supported by western blot 
analysis on both glycolytic and mitochondrial enzymes. 
Indeed, only the bis(carbene) provided an increase of 
the glycolytic enzymes GAPDH, ALDOA and TIP1 and 
decrease of the mitochondrial enzyme CS. Once again, 
the Au(NHC)2 effect in IGROV1 cells was in line with 
that in A2780 cells, whereas in SKOV3 cells it was less 
effective. Concerning the inhibitory potential toward TrxR 
the results were in line with those seen in A2780 cells. 
Indeed, both mono and bis(carbene) inhibit the enzyme 
activity in IGROV1 and SKOV3.
All these findings revealed that regardless of the 
cell lines, the bis(carbene) owns a cytotoxicity and an 
inhibitory capacity of TrxR greater than the monocarbene. 
On the other hand, the degree of antiproliferative and 
metabolic effects of the Au(NHC)2 differs depending on 
the cell line. A2780 and IGROV1 showed a very similar 
sensitivity towards Au(NHC)2, whereas SKOV3 appeared 
slightly more resistant. Thus, it is possible to suggest that 
the mechanism of action of the two carbenes may vary 
in part according to the cell lines. To better understand 
the mechanism of action of two carbenes and their 
potentialities as anticancer drugs we will extend our 
studies to further human cancer cell lines.
Concluding remarks
In conclusion, upon comparing the effects of these 
two gold carbene complexes through all the experiments 
with those of control cells, it clearly emerged that 
Au(NHC)2 is a far more effective compound versus the 
three cancer cell lines used in this study. Its behaviour is 
consistent with that of other delocalized lipophilic cations 
(DLCs) [54]. DLCs have been investigated as a new 
approach to cancer chemotherapy, which exploits their 
selective accumulation in mitochondria of cancer cells 
because of the elevated mitochondrial membrane potential 
that is a shared feature for many tumor cell lines.
Notably, Au(NHC)2 treatment leads to strong 
antiproliferative effects, potent inhibition of TrxR activity, 
decrease of mitochondrial respiration coupled with a lower 
mitochondrial membrane potential and higher glycolytic 
activity followed by a decrease of ATP level and finally 
cell death. Based on these evidences, both at the molecular 
and cellular level, we propose that the relevant cytotoxic 
actions produced by Au(NHC)2 are mainly the result of 
potent inhibition of thioredoxin reductase; the alterations 
of mitochondrial functions, elicited by profound TrxR 
inhibition, would lead to cell apoptosis. However, the exact 
identification of all the steps connecting the inhibition of 
TrxR to programmed cell death is not achieved yet and 
requires further studies.
MATERIALS AND METHODS
Materials
RPMI 1640 cell culture medium, fetal calf serum 
(FCS), and phosphate-buffered saline were obtained 
from Celbio (Milan, Italy); sulforhodamine B (SRB), 
Thiazolyl Blue Tetrazolium Bromide (MTT) and cisplatin 
were obtained from Sigma-Aldrich. General chemicals 
were purchased from Sigma-Aldrich, unless otherwise 
indicated.
LogP value determination
The octanol–water partition coefficients for 
carbene complexes were determined by modification 
of the reported shake-flask method [42]. Water (50 mL, 
distilled after milli-Q purification) and n-octanol (50 mL) 
were shaken together for 72 h to allow saturation of both 
phases. A solution of the complex was prepared in the 
water phase (3 × 10−3 M) and an equal volume of octanol 
was added. Biphasic solutions were mixed for ten minutes 
and then centrifuged for five minutes at 6000 rpm to allow 
separation. Concentration in both phases was determined 
by UV-Vis. Reported logP is defined as log[complex]oct/
[complex]wat. Final values were reported as mean of three 
determinations.
Cell lines and culture conditions
A2780 human ovarian cancer were purchased from 
the European Collection of Authenticated Cell Cultures 
(ECACC, a part of Public Health England) (Lot No. 
13J012, Sigma-Aldrich). IGROV1 and SKOV3 were 
a gift of Prof. Joseph R. Bertino (New Brunswick, NJ, 
USA). Cells were maintained in RPMI1640 medium 
supplemented with 10% of FCS and antibiotics at 37°C 
in a 5% CO2 atmosphere and sub-cultured twice weekly.
Antiproliferative activity
Cell proliferation inhibition of Au(NHC) and 
Au(NHC)2 was evaluated against the A2780 cell line 
according to the method described by Skehan et al. [43]. 
Gold carbene compounds were diluted in DMSO as stock 
solution (10 mM). Exponentially growing cells were 
seeded in 96-well microplates in RPMI 1640 supplemented 
with 10% FCS at a density of 8x103, for 24 h, prior to the 
addition of two carbene compounds. After 24 h, the medium 
was removed and replaced with fresh medium containing 
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concentrations of Au(NHC) or Au(NHC)2 ranging from 
0.003 to 100 μM and incubated for 72 h. For comparison 
purposes, the cytotoxicity of cisplatin was evaluated under 
the same experimental conditions. Then, cells were fixed 
with trichloroacetic acid and stained with sulforhodamine 
B (SRB) solution (0.4%), rinsed with 1% acetic acid and 
air-dried. After staining, SRB was dissolved in 10 mM 
Tris base. Optical density was read in a microplate reader 
interfaced with the software Microplate Manager/PV 
version 4.0 (Bio-Rad Laboratories) at 540 nm. The IC50 drug 
concentration resulting in a 50% reduction in the net protein 
content (as measured by SRB staining) in drug-treated cells 
as compared with untreated control cells was determined. 
The effect of carbenes on A2780 cell viability was also 
assessed with the MTT reduction. Briefly, we performed 
a time course at 12, 24, 48 and 72 h drug exposure with 
carbene concentration equal to 72 h-exposure IC50 value. 
At the end of incubation, cells were treated for 1 h at 37°C 
with 0.5 mg/ml MTT dissolved in PBS. Then, MTT was 
removed, cells were washed in PBS and 100 μl of stop 
solution (DMSO) were added. After 15 min of incubation 
at 37°C, optical density was read in the microplate reader 
interfaced with the software Microplate Manager/PV 
version 4.0 (Bio-Rad Laboratories) at 595 nm. Standard 
MTT proliferation assay was also used to determine IC50 
values of IGROV1 and SKOV3 cell lines after a 72-hr 
exposure to Au(NHC) or Au(NHC)2 or cisplatin.
Cell cycle analysis
Cell cycle analysis was assessed as previously reported 
[67]. Briefly, control, Au(NHC) and Au(NHC)2-treated (24, 
48 and 72 h) cells were trypsinized, washed with PBS, and 
fixed in 75% ice-cold ethanol at -20°C overnight. After 
rehydration with ice-cold PBS, cells were stained with PI/
RNase Staining Buffer (BD Biosciences, USA) and analysed 
using a FACSCanto Flow Cytometer (BD Biosciences). Data 
were analyzed by ModFit 3.0 software (BD Biosciences).
Assessment of cell death by flow cytometry
Cell death was analysed by TACS Annexin V/PI Kit 
(Trevigen) according to the manufacturer’s instructions. 
Briefly, control Au(NHC) and Au(NHC)2 treated cells for 
72 h were trypsinized, washed with PBS and resuspended 
in staining solution for 15 min in the dark. Then, cells 
were immediately analysed by FACSCanto flow cytometer 
(BD Biosciences). Gated cells were plotted on a dot-plot 
showing Annexin-V staining and propidium iodide (PI) 
staining. Index of apoptotic cells was determinate adding 
Annexin V positive (early apoptotic) cells to Annexin/PI 
positive ones (late apoptotic).
Assessment of caspase activity by flow cytometry
Caspase-3, caspase-8 and caspase-9 activity were 
analysed by flow cytometry as previously reported 
[68]. Briefly, control Au(NHC) and Au(NHC)2 A2780-
treated cells for 72 h were trypsinized, washed with PBS 
and resuspended in FAM-FLICATM Caspases solution 
(Caspase FLICA kit FAM-DEVD-FMK, ImmunoChemistry 
Technologies) for 1 h at 37°C, following the manufacturer’s 
instruction. Then, cells were washed twice with PBS, and 
analysed by FACSCanto flow cytometer (BD Biosciences).
Two-dimensional gel electrophoresis, image 
analysis and statistics
Cell growth conditions for proteomic analysis were 
the same as previously described [23]. Briefly, A2780 
cells were treated for 24 h with a concentration of the 
Au(NHC) or Au(NHC)2 equal to 72 h-exposure IC50-
values and to an equal concentration of DMSO as control. 
After treatment, cells were washed with phosphate-
buffered saline (PBS) and then lysed in RIPA buffer (50 
mM Tris-HCl pH 7.0, 1% (v/v) NP-40, 150 mM NaCl, 
2 mM ethylene glycol bis(2-aminoethyl ether)tetra-acetic 
acid, 100 mM NaF) containing a human protease inhibitor 
cocktail (Sigma-Aldrich). The cells were sonicated (15 
s) and protein extracts were clarified by centrifugation 
at 8000g, 4°C for 15 min. Proteins were precipitated 
following a chloroform/methanol protocol [69] and the 
protein pellets were resolved in a buffer containing 8 M 
urea, 4% (w/v) 3-cholamidopropyl dimethylammonium-
1-propane sulfonate (CHAPS), 65 mM dithioerythritol 
(DTE). The protein concentration was determined by 
the standard Bradford method (Bio-Rad Laboratories). 
Isoelectric focusing (IEF) was carried out on an IPGphor 
system (PROTEAN i12 system Bio-Rad Laboratories) 
using pH 3–10 gel strips of 18 cm. Strip were actively 
rehydrated at 30 V for 20 h in 350 μl of sample buffer 
containing 700 μg of proteins and supplemented with 
0.5% (v/v) carrier ampholyte (Bio-Rad Laboratories) and 
a trace of bromophenol blue. The IEF was performed at 
20°C under the following conditions: 250 V for 30 min, 
10,000 V for 2 h in gradient, 10,000 V until a total of 
43,000 V/h was reached, with a limiting current of the 
50 mA per strip. IPG strips were incubated for 15 min in 
equilibration buffer (50 mM Tris–Cl pH 8.8, 6 M urea, 
30% glycerol, 2% SDS) with 6.5 mM DTT and then 
in equilibration buffer with 2% iodoacetamide for an 
additional 15 min. The equilibrated strips were placed on 
top of 9–16% polyacrylamide linear gradient gels (18 cm x 
20 cm x1.5 mm) and embedded in 0.5% (w/v) heated low-
melting agarose in SDS electrophoresis running buffer 
(25 m M Tris, 192 m M glycine, 0.1% (w/v) SDS, pH 
8.3). The methylene-bisacrilamide was the cross-linker 
used in the 9–16% gradient. SDS-PAGE was performed 
in a PROTEAN II xi cell gel electrophoresis unit (Bio-
Rad Laboratories) at 10°C and at 40 mA per gel constant 
current, until the dye front reached the bottom of the gel, 
according to Hochstrasser et al. [70]. Gels were stained 
with colloidal Coomassie blue silver [71].
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To obtain statistically significant results, 
preparation of cell lysates for proteomic analysis was 
repeated independently three times for Au(NHC) and 
Au(NHC)2 –treated cells as well as for control cells 
(biological replicates). To minimize gel-to-gel variation, 
for each biological replicate, 2-DE were carried out twice 
(technical replicates). Therefore, for each cell line a total 
6 gels were analysed. Colloidal Coomassie blue silver-
stained gels were scanned using the Epson expression 
1680 PRO scanner. The gel images were saved with a 
resolution of 300 dpi and in 16-bit TIFF format. Image 
analysis was carried out using the Progenesis SameSpots 
software v4.0 (Nonlinear Dynamics, UK), which allows 
spot detection, background subtraction and protein 
spot volume quantification. The gel image showing the 
highest number of spots and the best protein pattern was 
chosen as the reference image and its spots were then 
matched across all gels. This reference image was used 
to quantify and normalize the spot volumes. The spot 
volumes were normalized in each gel as relative volume 
(volume percentage), by dividing the raw quantity of 
each spot by the total quantity of all the spots included 
in the reference gel. Statistical analysis was performed 
using default parameters of the Progenesis SameSpots 
Stat module. The log10-normalized spot volume was 
used for the analysis as the log transformation improves 
normality [72]. The univariate data analysis was 
performed as one-way ANOVA on each spot individually. 
Then, multivariate statistical analysis was applied on 
all the ANOVA p-values by the False Discovery Rate 
(FDR) correction method (q-value) [44]. Moreover, 
we performed a power analysis to assess the number of 
sample replicates that need to be analysed to confidently 
discover differentially abundant proteins. The accepted 
power threshold is >0.8 [45]. We considered statistically 
differentially abundant spots having a corrected p-value 
(q-value) ≤ 0.05 and a power ≥0.8. Moreover, these 
spots were subjected to multiple comparisons Tukey’s 
post-hoc test using by GraphPad Prism 6.0 software. The 
statistically differentially abundant spots were analysed 
by mass spectrometry.
Mass spectrometry analysis
Electrophoretic spots were manually excised, 
destained, and acetonitrile (ACN) dehydrated. A trypsin 
solution (0.25 mg/mL) in 50 mM ammonium bicarbonate 
was added for in-gel protein digestion by overnight 
incubation at 37°C. Solutions containing digested 
peptides were recovered and 20 mL of 1% TFA, 50% 
ACN were added to each spot and sonicated for 10 
min to maximize peptide recovery. At the end, for each 
spot all recovered peptide solutions were combined and 
concentrated. From each protein digest, 0.75 mL were 
spotted onto the MALDI target and allowed to air dry 
at room temperature. Then, 0.75 mL of matrix solution 
(saturated solution of α-cyano-4-hydroxycinnamic acid 
in 50% ACN and 0.5% TFA) was applied to the sample 
and crystallized by air drying at room temperature for 
5 min. Protein identification was carried out by peptide 
mass fingerprinting (PMF) on a MALDI Ultraflex III 
TOF/TOF200 mass spectrometer (Bruker Daltonics) 
equipped with a 200 Hz smartbeamt I laser. MS analysis 
was performed in the positive reflector mode according 
to defined parameters, as follows: 80 ns of delay; ion 
source 1: 25 kV; ion source 2: 21.75 kV; lens voltage: 
9.50 kV; reflector voltage: 26.30 kV; and reflector 2 
voltage: 14.00 kV. The applied laser wavelength and 
frequency were 353 nm and 100 Hz, respectively, and 
the percentage was set to 46%. Final mass spectra were 
produced by averaging 1500 laser shots targeting five 
different positions within the spot. Spectra were acquired 
automatically and the Flex Analysis software version 3.0 
(Bruker Daltonics) was used for their analysis and for the 
assignment of the peaks. The applied software generated 
a list of peaks up to 200, using a signal-to-noise ratio 
of 3 as the threshold for peak acceptance. Recorded 
spectra were calibrated using, as the internal standard, 
peptides arising from trypsin auto-proteolysis. The 
mass lists were filtered for contaminant removal: mass 
matrix related ions, trypsin autolysis and keratin peaks. 
Protein identification by Peptide Mass Fingerprint (PMF) 
search was established using MASCOT search engine 
version 2.1 (Matrix Science, London, UK, http://www.
matrixscience.com) through the UniProtKB database 
(http://www.uniprot.org/). Taxonomy was limited to 
Homo sapiens, a mass tolerance of 150 ppm was allowed, 
and the number of accepted missed cleavage sites was set 
to one. Alkylation of cysteine by carbamidomethylation 
was considered a fixed modification, while oxidation of 
methionine was considered as a possible modification. 
The criteria used to accept identifications included the 
extent of sequence coverage, the number of matched 
peptides, and a probabilistic score of p≤0.05. Peptide 
digests identified with a Mascot PMF score ≤ 70 were 
further analysed through MS/MS, using the same 
mass spectrometer. Two/three PMF peaks showing 
a high intensity were CID fragmented using Argon as 
collision gas, and MALDI-TOF/TOF tandem MS was 
performed in LIFT mode by software-controlled data 
acquisition. Fragmented ions were analysed using the 
Flex Analysis software version 3.0 (Bruker Daltonics). 
The MS/MS database searching was carried out using 
MASCOT search engine version 2.1 (Matrix Science, 
London, UK, http://www.matrixscience.com) through 
the UniProtKB database (http://www.uniprot.org/). The 
parameters applied for database searching were the same 
of PMF analysis with a fragment mass tolerance of 0.6 
Da. Mascot ion score, peptide coverage by “b” and “y” 
ions, and expected value were considered for protein 
identification. Individual ion scores > 25 are significant 
(p≤0.05).
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Bioinformatic functional analysis
To identify statistically over-represented 
(enriched) Gene Ontology (GO) terms and pathways 
among the differentially abundant proteins identified 
by MS analysis, we used the Webgestalt online tool 
(“WEB-based GEne SeT AnaLysis Toolkit”) (http://
www.webgestalt.org) against Gene Ontology (GO), 
Kyoto Encyclopedia of Genes and Genomes (KEGG), 
and Panther databases [46–48]. The list of UniProtKB 
(http://www.uniprot.org/) accession number (AC) of 
the identified proteins was loaded into the online tool. 
After submission of the list, functional classification was 
performed based on Gene Ontology against the Homo 
sapiens genome. The one-sided Fisher’s exact test or 
the hypergeometric distribution was used to check for 
significant over-representation. Then, the Benjamini-
Hochberg correction was performed to globally correct 
the p-value controlling the family wide false discovery 
rate (corrected p-value ≤ 0.1).
Glucose uptake
Glucose uptake was evaluated in control, Au(NHC) 
and Au(NHC)2 treated cells (24 and 48 h) as previously 
described [73]. Briefly, controls and treated-cells were 
incubated for 12 h in starvation medium containing low 
glucose concentration (DMEM low glucose, supplemented 
with 10% of FCS) and compounds. Then cells were 
washed in PBS and incubated with a buffered solution 
(140 mmol/L NaCl, 20 mmol/L Hepes/Na, 2.5 mmol/L 
MgSO4, 1 mmol/L CaCl2, and 5 mmol/L KCl, pH 7.4) 
containing 0.5 μCi/mL[U-14C] glucose. Cells were 
subsequently washed with cold PBS and lysed with 0.1 
mol/L NaOH. Incorporated radioactivity was assayed by 
liquid scintillation counting and normalized on protein 
content.
Measurement of oxygen consumption
Control and Au(NHC) and Au(NHC)2 treated 
cells (24 and 48 h), were trypsinized, washed with PBS 
and resuspended in complete RPMI medium at the 
concentration of 106 cells/mL. One ml of cell suspension 
was transferred to an airtight chamber maintained at 37°C 
and oxygen consumption was measured using a Clark-type 
O2 electrode (Hansatech) Oxygen content was monitored 
for at least 10 min. The rate of decrease in oxygen content, 
related to protein amount was taken as index of the 
respiratory capability [74].
Measurement of ATP level
ATP amount was determined with ATP 
Determination Kit (Molecular Probes) according to 
manufacturing instruction. ATP amount was normalized 
on protein content of the same sample.
Lactate assay
Lactate amount was assayed in cells medium with 
K-LATE kit (Megazyme) according manufacturer’s 
instructions. Lactate content was normalized on protein 
content of the same sample.
Western blot analysis
A2780, IGROV1 and SKOV3 cells were treated 
for 24, 48 h or 72 h with mono and bis(carbene) at a 
concentration corresponding to their 72 h-exposure 
IC50-dose. Cells were lysed in RIPA buffer containing a 
human protease inhibitor cocktail and 20 μg of proteins 
were separated by 4-20% precast SDS-PAGE (Bio-Rad 
Laboratories) and transferred to PVDF membranes (Bio-
Rad Laboratories). Primary antibody (GAPDH, Sigma 
Aldrich; AldoA, Thermo Scientific; TPI1, Santa Cruz; 
COF1, Thermo Scientific; CS, Santa Cruz; Bcl2, and Bax, 
Santa Cruz) were diluted 1:1000 in 2% Milk and incubated 
overnight at 4°C. After incubation with horseradish 
peroxidase (HRP)-conjugated anti-mouse IgG (1:2000) 
(Santa Cruz Laboratories), immune complexes were 
detected with the enhanced chemiluminescence (ECL) 
detection system (GE Healthcare). The PVDF membrane 
was exposed to autoradiographic films (Pierce) for 1–20 
minutes. For quantification, the blot was subjected to 
densitometric analysis using ImageJ2 program [75]. The 
intensity of the immunostained bands was normalized 
with the total protein intensities measured by Coomassie 
brilliant blue R-250 from the same PVDF membrane blot.
TrxR inhibition assay
A2780, IGROV1 and SKOV3 cells were treated for 24 
h with Au(NHC) or Au(NHC)2 concentration corresponding 
to their 72 h-exposure IC50-dose. Cells were lysed in RIPA 
buffer containing a human protease inhibitor cocktail (Sigma-
Aldrich), and 30 μg of proteins were used for the enzymatic 
assay. The TrxR inhibition was assessed using a commercial 
colorimetric assay kit (Sigma-Aldrich, CS0170) based on 
the reduction of 5,5’-dithiobis(2-nitrobenzoic) acid (DTNB) 
with NADPH to 5-thio-2-nitrobenzoic acid (TNB), according 
to the manufacturer’s instructions. This kit also contains an 
inhibitor solution of mammalian thioredoxin reductase. 
Since several enzymes present in biological sample can 
reduce DTNB, the specific inhibitor is used to determine the 
reduction of DTNB due only to TrxR activity. Experiments 
were performed in triplicate. Results were normalized to the 
cellular protein content.
ROS formation
ROS generation was measured using 
2′,7′-dichlorfluorescein-diacetate (DCF-DA), a fluorogenic 
dye that binds to ROS. Within the cell, DCFDA is deacetylated 
by cellular esterase to a non-fluorescent compound, which 
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is later oxidized by cellular ROS into the highly fluorescent 
compound 2′, 7′-dichlorofluorescein (DCF). A total of 5 μM 
DCF-DA was added to sub-confluent cells for 3 to 30 min. 
Cells were lysed in 1 mL RIPA buffer containing 1% Triton 
X-100 and fluorescence was immediately analysed using a 
fluorescence spectrophotometer (excitation wavelength: 488 
nm, emission wavelength: 510 nm). The fluorescence values 
were normalized for total protein content. Mitochondrial 
superoxide anion production was measured using the 
fluorogenic dye MitoSOX Red (Molecular Probe). Cells 
suspension was incubated for 15 min with 3 μM MitoSOX 
Red, washed in PBS and analysed by FACSCanto flow 
cytometer (BD Biosciences).
Measurement of mitochondrial potential 
membrane
Mitochondrial membrane potential was assessed 
with 1,1′,3,3,3′,3′-hexamethylindodicarbo- cyanine 
iodide, DiIC1(5) (1,1′,3,3,3,3′-hexamethylindodicarbo-
cyanine iodide) (MitoProbeTM), a cationic cyanine dyes 
that accumulates primarily in mitochondria with active 
membrane potentials. Cells suspensions were washed 
twice with PBS and incubated, in the dark, for 20 min. 
at 37°C with DiIC1(5) (50 nM) in PBS. After labelling, 
cells were washed, resuspended in PBS and analysed by 
FACSCanto flow cytometer (BD Biosciences).
Statistical analysis
The non-proteomic experiments were carried out, at 
least, in triplicate. Statistical analysis was performed by one-
way ANOVA test followed by Tuckey’s multiple comparisons 
test using Graphpad Prism 6. A p-value≤0.05 was considered 
statistically significant. Results were reported as mean ±SD.
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